The Use of Molecular Pathway Inhibitors in the Treatment of Osteosarcoma
Authors:
- Adel MahjoubAMAdel Mahjoub
- Jared A. CrastoJCJared A. Crasto
- Jonathan MandellJMJonathan Mandell
- Mitchell S. FourmanMFMitchell S. Fourman
- Rashmi AgarwalRARashmi Agarwal
- Kurt R. WeissKWKurt R. Weiss
Open Access
- 26 April 2017
- book chapter
- Published by IntechOpen
Abstract
The Use of Molecular Pathway Inhibitors in the Treatment of Osteosarcoma | InTechOpen, Published on: 2017-04-26. Authors: Adel Mahjoub, Jared A. Crasto, Jonathan Mandell, etKeywords
This publication has 85 references indexed in Scilit:
- Aldehyde dehydrogenases and cancer stem cellsCancer Letters, 2015
- Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program databaseCancer Epidemiology, 2015
- Reactive Oxygen Species in Cancer Stem CellsAntioxidants & Redox Signaling, 2012
- Aldehyde Dehydrogenase 1 A1–Positive Cell Population Is Enriched in Tumor-Initiating Cells and Associated with Progression of Bladder CancerCancer Epidemiology, Biomarkers & Prevention, 2010
- Molecular Biology and Therapeutics in Musculoskeletal Oncology*Journal of Bone and Joint Surgery, 2009
- ALDH1 as a Functional Marker of Cancer Stem and Progenitor CellsStem Cells and Development, 2009
- High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic abilityJournal of Cellular and Molecular Medicine, 2008
- Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamilyExpert Opinion on Drug Metabolism & Toxicology, 2008
- Chronic Health Conditions in Adult Survivors of Childhood CancerNew England Journal of Medicine, 2006
- DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesisAlcohol, 2005